Back to Results
First PageMeta Content



DALCOR PHARMA LICENSES A LATE-STAGE INVESTIGATIONAL CARDIOVASCULAR DRUG FOLLOWING MAJOR SCIENTIFIC DISCOVERY New company DalCor to sponsor global phase III clinical trial San Mateo, California, June 8, 2015 – DalCor Ph
Add to Reading List

Open Document

File Size: 49,75 KB

Share Result on Facebook

City

San Mateo / /

Company

Sanderling Ventures Charlotte Shropshire / DalCor Pharmaceuticals Inc. / Sanderling Ventures LLC / DALCOR PHARMA / /

Country

United States / /

Currency

USD / /

/

Event

Business Partnership / FDA Phase / /

Facility

Women’s Hospital / University of Montreal / Montreal Heart Institute / /

IndustryTerm

healthcare system / active management / early stage technologies / /

MedicalCondition

Cardiovascular disease / coronary atherosclerosis / heart attack / documented recent Acute Coronary Syndrome / /

Organization

Harvard Medical School / Cardiovascular Division / Research Center / Clinical Research Organization / Montreal Heart Institute / Montreal Heart Institute Foundation / Women’s Hospital in Boston / Montreal Health Innovations Coordinating Centre / University of Montreal / Study Executive Committee / Research Center at MHI / /

Person

Drs Jean-Claude Tardif / Jean-Claude Tardif / Marc Pfeffer / Robert McNeil / Paul David / Lise Plante / Louise Proulx / /

/

Position

CEO / MAJOR SCIENTIFIC DISCOVERY / Director / Director of Institutional Investment Phone / Managing Director / Director Communications and Marketing / Physician / researcher / Chair Research / Ph.D Chief Development Officer Phone / Professor of Medicine / /

Product

Dal-GenE / CARDIOVASCULAR DRUG / /

ProvinceOrState

Quebec / California / /

Technology

early stage technologies / genotype / /

URL

www.sanderling.com / www.dalcorpharma.com / /

SocialTag